Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-12-01T00:52:40.513Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevalence, Treatment, and Outcome of Infection Due to Extended-Spectrum β-Lactamase–Producing Microorganisms

Published online by Cambridge University Press:  21 June 2016

Anucha Apisarnthanarak  and
Linda M. Mundy
Anucha Apisarnthanarak*
Affiliation:
Division of Infectious Diseases, Faculty of Medicine, Thammasart University Hospital, Pratumthani, Thailand
Linda M. Mundy
Affiliation:
Saint Louis University School of Public Health, St. Louis, Missouri
*
Division of Infectious Diseases, Faculty of Medicine, Thammasart University Hospital, Pratumthani, Thailand12120 ([email protected])
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Infection Control & Hospital Epidemiology , Volume 27 , Issue 3 , March 2006 , pp. 326 - 327
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2006

References

1.Kang, CI, Kim, SH, Kim, DM, et al. Risk factors for and clinical outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25:860–867.CrossRefGoogle ScholarPubMed
2.NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. 14th Informational supplement. Wayne, PA: NCCLS; 2004. NCCLS document M100-S14.Google Scholar
3.Horan, TC, Gaynes, RP, Martone, WJ, Jarvis, WR, Emori, TG. CDC definitions for nosocomial infections. Am J Infect Control 1992; 20:271–274.CrossRefGoogle Scholar
4.Emery, CL, Weymouth, LA. Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35:2061–2067.CrossRefGoogle Scholar
5.Karas, JA, Pillay, DG, Muckart, D, Sturm, AW. Treatment failure due to extended spectrum beta-lactamases. J Antimicrob Chemother 1996; 37:203–204.CrossRefGoogle Scholar
6.Jorgensen, JH, Turnidge, JD, Washington, JA. Antibacteria susceptibility tests: dilution and disk diffusion methods. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: American Society of Microbiology; 1999.Google Scholar
7.Paterson, DL, Ko, WC, Von Gottberg, A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206–2012.CrossRefGoogle ScholarPubMed